Developmental Research Program

发展研究计划

• 批准号: 10482377
• 负责人: George Ioannou
• 金额: $ 6.39万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-06 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10482377
• 关键词: Alaska Native; American Indians; Area; Basic Science; Biometry; Cancer Center Planning Grant; Cancer Research Project; Cessation of life; Cherokee Indian; Clinical; Clinical Sciences; Collaborations; Colorectal Cancer; Development; Early Diagnosis; Epidemiology; Etiology; Face; Faculty; Feedback; Foundations; Fred Hutchinson Cancer Research Center; Functional disorder; Funding; Goals; Government; Grant; Health Services; Incidence; Infrastructure; Institution; Investments; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of prostate; Manuscripts; Medical center; Monitor; Morbidity - disease rate; Native-Born; Outcome; Patients; Persons; Phase; Population; Population Study; Prevention; Primary carcinoma of the liver cells; Prognosis; Program Research Project Grants; Quality of life; Reporting; Research; Research Personnel; Research Project Grants; Research Proposals; Resources; Scientist; Site; Source; Structure; Talents; Texas; Therapeutic; Time; Translational Research; Travel; Universities; Washington; Woman; Work; anticancer research; base; cancer health disparity; cancer therapy; design; disparity elimination; ethnic diversity; experience; feasibility testing; gender diversity; improved; innovation; interest; malignant breast neoplasm; medical schools; meetings; member; men; mortality; multidisciplinary; novel; programs; racial and ethnic; research study; survivorship; translational approach; translational goal; tribal health

ABSTRACT: DEVELOPMENTAL AND RESEARCH PROGRAM CORE The Developmental Research Program (DRP) of the Liver Cancer in American Indians/Alaska Natives (AI/AN) Disparities (Li-CAD) P20 Program will support early-phase projects that have the potential to open new areas of translational liver cancer research and ultimately, contribute to reducing morbidity and mortality and improving quality-of-life for patients with hepatocellular carcinoma (HCC). Projects funded under the DRP are intended to rapidly advance a new idea or concept that has the potential to substantially impact our understanding of liver cancer to eliminate disparities and improve surveillance, early detection, and treatment of HCC in AI/AN persons and thereby reduce or eliminate HCC-related mortality. The infrastructure of the DRP will establish mechanisms to quickly respond to translational research opportunities within the Li-CAD P20 Program institutions that require support to advance hypotheses or confirm feasibility in order to justify larger resource investments. Developmental projects will include research in basic science, clinical science, and population-based studies, and will build collaborations between Li-CAD sites and other institutions with P20 Programs and SPOREs in liver cancer and disparities research. Developmental projects may encompass a wide range of liver cancer research and treatment areas, including basic science, etiology and prevention (primary and secondary), early detection, prognosis, therapeutics, and survivorship. Collectively, the DRP is structured to strengthen collaborations between Li-CAD sites and initiate interactions with other institutions with P20 Programs and SPOREs in liver cancer. DRP proposals will be supported based on their potential to mature an original idea or concept into a translational research project that will successfully attain independent funding, either within a subsequent P50 or from other government or foundation sources. In addition, the DRP is designed to attract senior investigators with diverse scientific expertise and junior investigators new to translational liver cancer research. The Specific Aims for the Developmental Research Program are to: 1. Stimulate the development of innovative, impactful, early-phase research studies that include multidisciplinary interactions with basic, clinical, and population scientists across the Li-CAD institutions; 2. Provide funding (1-2 years) and infrastructure (e.g., biospecimens, biostatistical support) to rapidly test the feasibility of original investigator-initiated projects in all areas of HCC research; 3. Prioritize funding to rapidly exploit new opportunities or support specific areas of strategic importance for advancing the translational research goals of the Li-CAD P20 Program; and 4. Monitor (and facilitate) the progress of each DRP project and consider their advancement to a full P50 SPORE project.

摘要：发展和研究计划核心 美国印第安人/阿拉斯加土著人（AI/AN）的肝癌的发展研究计划（DRP） 差异（LI-CAD）P20计划将支持有可能开放新领域的早期阶段项目 翻译肝癌研究，最终有助于降低发病率和死亡率并改善 肝细胞癌（HCC）患者的生活质量。根据DRP资助的项目旨在 迅速发展一个新的想法或概念，有可能实质上影响我们对肝脏的理解 癌症以消除差异并改善AI/AN人的HCC的监视，早期检测和治疗 从而降低或消除与HCC相关的死亡率。 DRP的基础设施将建立机制 快速响应LI-CAD P20计划机构中的转化研究机会 支持推进假设或确认可行性，以证明更大的资源投资是合理的。 发展项目将包括基础科学，临床科学和基于人群的研究， 并将在LI-CAD网站和其他机构之间建立合作 癌症和差异研究。 发展项目可能包括广泛的肝癌研究和治疗领域，包括 基础科学，病因和预防（主要和次要），早期检测，预后，治疗学和 生存。总体而言，DRP的结构是加强LI-CAD站点之间的合作并启动 与其他机构与肝癌中P20计划和孢子的相互作用。 DRP的建议将是 基于他们将原始思想或概念成熟到转化研究项目中的潜力 将在随后的P50或其他政府或其他政府中成功获得独立资金或 基础资源。此外，DRP旨在吸引具有多样科学的高级调查员 专业知识和初级研究人员是转化肝癌研究的新手。 发展研究计划的具体目的是： 1。刺激创新，有影响力的早期研究研究的发展，包括 与LI-CAD机构的基本，临床和人群科学家的多学科互动； 2。提供资金（1-2年）和基础设施（例如生物测量，生物统计学支持）来快速测试 HCC研究所有领域的原始研究人员发动的项目的可行性； 3。优先考虑资金以快速利用新的机会或支持特定战略重要性领域 促进LI-CAD P20计划的翻译研究目标；和 4.监视（并促进）每个DRP项目的进度，并考虑其进步到完整的P50 孢子项目。